NCT06045780 HO-1/CREB3 Modulates Golgi Stress in Patients With Sepsis
| NCT ID | NCT06045780 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Nankai Hospital |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-09-15 |
| Primary Completion | 2024-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-09-15 with a primary completion date of 2024-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was an ambispective observational cohort study that included sepsis patients hospitalized in the Intensive care unit (ICU) of the Nankai Hospital. All patients met the consensus criteria of sepsis-3. The purpose of this study is to investigate the valuable biomarkers for the severity of sepsis and predictors of 30-day mortality for patients with sepsis.
Eligibility Criteria
Inclusion Criteria: 1. Males or females over the age of 18; 2. Sepsis was diagnosed within 48h which meets SPESIS 3 criteria; 3. Capable of understanding the purpose and risk of the study; 4. Patients or proxy must give written informed consent before any assessment is performed. Exclusion Criteria: 1. Pregnancy, lactation or perinatal period; 2. Breast carcinoma; 3. HIV seropositive or Syphilis seropositive; 4. Any clinical-relevant condition that might affect study participation and/or study results; 5. Participation in any other intervention trial; 6. Unwillingness or inability to following the study protocol in the investigators opinion.
Contact & Investigator
Jianbo Yu, MD
STUDY DIRECTOR
Tianjin Nankai Hospital
Frequently Asked Questions
Who can join the NCT06045780 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06045780 currently recruiting?
Yes, NCT06045780 is actively recruiting participants. Contact the research team at 30717008@nankai.edu.cn for enrollment information.
Where is the NCT06045780 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06045780 clinical trial?
NCT06045780 is sponsored by Tianjin Nankai Hospital. The principal investigator is Jianbo Yu, MD at Tianjin Nankai Hospital. The trial plans to enroll 150 participants.